Table 1.
Impact of (heterophilic) chemokine complexes on function-proposed mechanisms.
Dimer | Function | Cellular Effect | References |
---|---|---|---|
Enhancing effects | |||
CXCL4●CCL5 | Prevention of CCR5 internalization, prolonged signaling | Increased monocyte arrest | [61,71,85,86] |
CCL5●HNP1 | Binding to CCR5 | Increased recruitment and adhesion of monocyte, and macrophage recruitment | [87] |
CCL5●CCL17 | Promotion of CCR4•CCR5 heterodimerization | Promotes Treg homeostasis | [61] |
CXCL10●CCL22 | Activation of CCR4, increased ERK phosphorylation | Increased T cell migration | [64] |
CCL2●CXCL12 | Activation of CCR2 on macrophages, increased IL-10 production and secretion | M2 macrophage polarization, IL-10-dependant B and T cell activation | [68,69] |
CXCL12●HMGB1 | Ternary CXCR4 complex, biased agonism, β-arrestin 1/2-recruitment, actin polymerization, receptor internalization and degradation, increased intracellular Ca2+ mobilization and ERK phosphorylation | Increased leukocyte migration | [88,89] |
CXCL12●CXCL12 | Binding to and internalization of ACKR1 | Binding to transfected MDCK cells and primary human Duffy-positive erythrocytes | [52] |
CXCL4●Gal1 | Modulation of the galectin glycan-binding affinity and specificity | Increased apoptotic activity of CD3+ and CD3+CD8+ T cells | [90] |
Inhibitory effects | |||
CCL5●CXCL12 | Biased CXCR4 antagonism, signaling through PI3K, Syk and BTK affected | Inhibition of platelet aggregation | [61,67] |
CXCL4L1●MIF | Prevention of CXCR4 activation | Inhibition of MIF-stimulated thrombus formation and T cell migration | [62] |
CXCL8●CXCL4 | No experimental data addressing the molecular mechanism | Prevents CXCL8-induced activation of hematopietic progenitors | [74,75] |
CXCL4●CXCL12 | Ternary CXCR4 complex, biased antagonism, increased Ca2+ release | Suppression of MDA-MB 231 breast cancer cell migration | [76,77] |
CXCL1●Evasin3 | Absence of binding to CXCR2 | Reduction of neutrophil migration | [91] |
CXCL12●Gal3 | Ternary complex with CXCR4, biased antagonism, decreased β-arrestin recruitment and cAMP production | Inhibition of CD4+ T cell, monocyte and neutrophil recruitment | [92] |
CCL5●Gal9 | Modulation of the galectin glycan-binding affinity andspecificity | Decreased apoptotic activity of CD3+ and CD3+CD4+ T cells | [90] |
CXCL12●CXCL12 | Biased CXCR4 antagonism and heterotrimeric G proteins, inhibition of adenylate cyclase, increased Ca2+ release and actin polymerization | Inhibition of colonic carcinoma and murine melanoma metastasis | [38,49] |
Neutral effects | |||
CXCL1●CXCL7 | Activation of CXCR2, Ca2+ release, complex interaction with GAGs | CXCR2-transfected HL60 cells response comparable to that with the CXCL7/CXCL1 mixture | [40] |
CXCL8●CXCL8 | Ca2+ mobilization, CXCR1/2 activation and phosphorylation, ERK phosphorylation, desensitization, β-arrestin 1-dependant CXCR2 internalization | CXCR2-induced migration of HMEC and CXCR2-transfected RBL-2H3 cells | [50] |
CXCL7●CXCL7 | Activation of CXCR2, Ca2+ release | CXCR2-transfected HL60 cells response comparable to that with the monomer | [39] |
CXCL1●CXCL1 | Binding and activation of CXCR2, Ca2+ release, ERK phosphorylation | CXCR2-HL60 cells migration comparable to that with the monomer | [51] |